Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of a Novel Bivalent Norovirus Vaccine in Healthy Volunteers
NCT06944717Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Viral Vector Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of VXA-GI.1.NN and VXA-G2.4-NS in norovirus infection (3 arms), sponsored by Vaxart, Inc. Primary endpoints: Number of Participants Experiencing Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) at 7 days, Duration of Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) at 1 year and 11 more. Started Mar 2025; status: completed.
02
Drugs
VXA-GI.1.NNVXA-G2.4-NS
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT06944717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944717.